{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:42:02Z","timestamp":1790613722317,"version":"4.1.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":62,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Youth Innovation Project of Sichuan Medical Association","award":["No. Q20250004"],"award-info":[{"award-number":["No. Q20250004"]}]},{"DOI":"10.13039\/501100019971","name":"Luzhou Science and Technology Bureau","doi-asserted-by":"publisher","award":["No. 2025JYJ014"],"award-info":[{"award-number":["No. 2025JYJ014"]}],"id":[{"id":"10.13039\/501100019971","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Health Commission of Sichuan Province Medical Science and Technology Program","award":["No. 24QNMP093"],"award-info":[{"award-number":["No. 24QNMP093"]}]},{"name":"Special Funding for Cultivation of Defense Talents","award":["No. CW202410"],"award-info":[{"award-number":["No. CW202410"]}]},{"name":"Sichuan Province Science and Technology Project","award":["No. 2026NSFSC0577"],"award-info":[{"award-number":["No. 2026NSFSC0577"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hepatocellular carcinoma (HCC) is characterized by high heterogeneity, making early diagnosis and systemic therapy challenging. Glypican-3 (GPC-3) targeted radiopharmaceuticals are promising tools for HCC. This review summarizes the development of this field from a platform-centric perspective, comparing various molecular targeting vectors designed against GPC-3.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main body<\/jats:title>\n                    <jats:p>The development of GPC-3 radiopharmaceuticals has evolved from slow-clearing monoclonal antibodies (mAbs) to rapidly excreted antibody fragments, peptides and other promising platforms. Early platform selection faced a compromise between molecular size and tumor retention. Current strategies tend to optimize pharmacokinetic profiles through chemical modifications, including the application of albumin-binding groups, PEGylation (polyethylene glycol modification), cyclization and integrating these strategies. These engineering approaches aim to provide an optimal signal-to-noise ratio in same-day imaging for diagnosis, while ensuring sustained tumor retention required for targeted radionuclide therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Future clinical translation will require further exploration of optimal pharmacokinetic properties to achieve a better balance between diagnostic and therapeutic capabilities, which is essential to promote GPC-3 theranostics into routine clinical practice. Furthermore, emerging strategies such as shifting towards more potent alpha-radionuclides; moving from single-targeting to multi-targeting strategies, such as GPC-3 and prostate-specific membrane antigen (PSMA); and synergizing radionuclide therapy with immunotherapy (e.g., immune checkpoint inhibitors) are expected to become key to overcoming tumor heterogeneity and prolonging patient survival.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13550-026-01454-4","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T16:16:24Z","timestamp":1779812184000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Glypican-3 targeted radiopharmaceuticals for hepatocellular carcinoma: a review of molecular platforms"],"prefix":"10.1186","volume":"16","author":[{"given":"Yue","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1010-5020","authenticated-orcid":false,"given":"Lin","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"1454_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin Wiley. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin Wiley"},{"key":"1454_CR2","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","volume":"400","author":"A Vogel","year":"2022","unstructured":"Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet. 2022;400:1345\u201362. https:\/\/doi.org\/10.1016\/S0140-6736(22)01200-4.","journal-title":"Lancet"},{"key":"1454_CR3","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/s41571-023-00825-3","volume":"20","author":"AG Singal","year":"2023","unstructured":"Singal AG, Kanwal F, Llovet JM. Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy. Nat Rev Clin Oncol. 2023;20:864\u201384. https:\/\/doi.org\/10.1038\/s41571-023-00825-3.","journal-title":"Nat Rev Clin Oncol"},{"key":"1454_CR4","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.3390\/cancers15071975","volume":"15","author":"N Nyakale","year":"2023","unstructured":"Nyakale N, Filippi L, Aldous C, Sathekge M. Update on PET Radiopharmaceuticals for Imaging Hepatocellular Carcinoma. Cancers MDPI AG. 2023;15:1975. https:\/\/doi.org\/10.3390\/cancers15071975.","journal-title":"Cancers MDPI AG"},{"key":"1454_CR5","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1080\/17434440.2019.1608817","volume":"16","author":"L Filippi","year":"2019","unstructured":"Filippi L, Schillaci O, Bagni O. Recent advances in PET probes for hepatocellular carcinoma characterization. Expert Rev Med Devices Informa UK Ltd. 2019;16:341\u201350. https:\/\/doi.org\/10.1080\/17434440.2019.1608817.","journal-title":"Expert Rev Med Devices Informa UK Ltd"},{"key":"1454_CR6","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1001\/jamasurg.2022.7989","volume":"158","author":"ZJ Brown","year":"2023","unstructured":"Brown ZJ, Tsilimigras DI, Ruff SM, Mohseni A, Kamel IR, Cloyd JM, et al. Management of Hepatocellular Carcinoma: A Review. JAMA Surg Am Med Association (AMA). 2023;158:410. https:\/\/doi.org\/10.1001\/jamasurg.2022.7989.","journal-title":"JAMA Surg Am Med Association (AMA)"},{"key":"1454_CR7","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.ejca.2010.10.024","volume":"47","author":"M Ho","year":"2011","unstructured":"Ho M, Kim H. Glypican-3: A new target for cancer immunotherapy. Eur J Cancer Elsevier BV. 2011;47:333\u20138. https:\/\/doi.org\/10.1016\/j.ejca.2010.10.024.","journal-title":"Eur J Cancer Elsevier BV"},{"key":"1454_CR8","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.7150\/jca.39972","volume":"11","author":"M Guo","year":"2020","unstructured":"Guo M, Zhang H, Zheng J, Liu Y. Glypican-3: A New Target for Diagnosis and Treatment of Hepatocellular Carcinoma. J Cancer Ivyspring Int Publisher. 2020;11:2008\u201321. https:\/\/doi.org\/10.7150\/jca.39972.","journal-title":"J Cancer Ivyspring Int Publisher"},{"key":"1454_CR9","doi-asserted-by":"publisher","first-page":"824208","DOI":"10.3389\/fonc.2022.824208","volume":"12","author":"X Zheng","year":"2022","unstructured":"Zheng X, Liu X, Lei Y, Wang G, Liu M. Glypican-3: A Novel and Promising Target for the Treatment of Hepatocellular Carcinoma. Front Oncol. 2022;12:824208. https:\/\/doi.org\/10.3389\/fonc.2022.824208.","journal-title":"Front Oncol"},{"key":"1454_CR10","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.3390\/biomedicines13071570","volume":"13","author":"L Filippi","year":"2025","unstructured":"Filippi L, Frantellizzi V, Urso L, De Vincentis G, Urbano N. Targeting Glypican-3 in Liver Cancer: Groundbreaking Preclinical and Clinical Insights. Biomedicines MDPI AG. 2025;13:1570. https:\/\/doi.org\/10.3390\/biomedicines13071570.","journal-title":"Biomedicines MDPI AG"},{"key":"1454_CR11","doi-asserted-by":"publisher","first-page":"3870","DOI":"10.3390\/cancers12123870","volume":"12","author":"RD Houvast","year":"2020","unstructured":"Houvast RD, Vankemmelbeke M, Durrant LG, Wuhrer M, Baart VM, Kuppen PJK, et al. Targeting Glycans and Heavily Glycosylated Proteins for Tumor Imaging. Cancers MDPI AG. 2020;12:3870. https:\/\/doi.org\/10.3390\/cancers12123870.","journal-title":"Cancers MDPI AG"},{"key":"1454_CR12","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1002\/med.21455","volume":"38","author":"F Zhou","year":"2018","unstructured":"Zhou F, Shang W, Yu X, Tian J. Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment. Med Res Rev Wiley. 2018;38:741\u201367. https:\/\/doi.org\/10.1002\/med.21455.","journal-title":"Med Res Rev Wiley"},{"key":"1454_CR13","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1186\/s40001-024-02073-2","volume":"29","author":"AR Devan","year":"2024","unstructured":"Devan AR, Nair B, Pradeep GK, Alexander R, Vinod BS, Nath LR, et al. The role of glypican-3 in hepatocellular carcinoma: Insights into diagnosis and therapeutic potential. Eur J Med Res. 2024;29:490. https:\/\/doi.org\/10.1186\/s40001-024-02073-2.","journal-title":"Eur J Med Res"},{"key":"1454_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/2560650","volume":"2019","author":"G Yao","year":"2019","unstructured":"Yao G, Yin J, Wang Q, Dong R, Lu J. Glypican-3 Enhances Reprogramming of Glucose Metabolism in Liver Cancer Cells. BioMed Res Int Wiley. 2019;2019:1\u201311. https:\/\/doi.org\/10.1155\/2019\/2560650.","journal-title":"BioMed Res Int Wiley"},{"key":"1454_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1026245","author":"X Wang","year":"2023","unstructured":"Wang X, Li L, Wang L, Chen M. The expression of Ki-67 and Glypican\u2009\u2013\u20093 in hepatocellular carcinoma was evaluated by comparing DWI and 18F-FDG PET\/CT. Front Oncol [Internet]. Front Media SA. 2023. https:\/\/doi.org\/10.3389\/fonc.2023.1026245. [cited 2025 July 21];13.","journal-title":"Front Media SA"},{"key":"1454_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/203601","volume":"2014","author":"FCJ Van De Watering","year":"2014","unstructured":"Van De Watering FCJ, Rijpkema M, Perk L, Brinkmann U, Oyen WJG, Boerman OC. Zirconium-89 Labeled Antibodies: A New Tool for Molecular Imaging in Cancer Patients. BioMed Res Int. 2014;2014:1\u201313. https:\/\/doi.org\/10.1155\/2014\/203601.","journal-title":"BioMed Res Int"},{"key":"1454_CR17","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2967\/jnumed.113.132118","volume":"55","author":"JG Sham","year":"2014","unstructured":"Sham JG, Kievit FM, Grierson JR, Miyaoka RS, Yeh MM, Zhang M, et al. Glypican-3\u2013Targeted 89Zr PET Imaging of Hepatocellular Carcinoma. J Nucl Med. 2014;55:799\u2013804. https:\/\/doi.org\/10.2967\/jnumed.113.132118.","journal-title":"J Nucl Med"},{"key":"1454_CR18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13550-023-00980-9","volume":"13","author":"KP Labadie","year":"2023","unstructured":"Labadie KP, Lehnert AL, Kenoyer AL, Hamlin DK, Ludwig AD, Utria AF, et al. Glypican-3 targeted positron emission tomography detects sub-centimeter tumors in a xenograft model of hepatocellular carcinoma. EJNMMI Res. 2023;13:35. https:\/\/doi.org\/10.1186\/s13550-023-00980-9.","journal-title":"EJNMMI Res"},{"key":"1454_CR19","doi-asserted-by":"publisher","first-page":"6964","DOI":"10.1016\/j.biomaterials.2014.04.089","volume":"35","author":"X Yang","year":"2014","unstructured":"Yang X, Liu H, Sun CK, Natarajan A, Hu X, Wang X, et al. Imaging of hepatocellular carcinoma patient-derived xenografts using 89Zr-labeled anti-glypican-3 monoclonal antibody. Biomaterials. 2014;35:6964\u201371. https:\/\/doi.org\/10.1016\/j.biomaterials.2014.04.089.","journal-title":"Biomaterials"},{"key":"1454_CR20","doi-asserted-by":"publisher","first-page":"3977","DOI":"10.3390\/cancers13163977","volume":"13","author":"A Natarajan","year":"2021","unstructured":"Natarajan A, Zhang H, Ye W, Huttad L, Tan M, Chua M-S, et al. A Humanized Anti-GPC3 Antibody for Immuno-Positron Emission Tomography Imaging of Orthotopic Mouse Model of Patient-Derived Hepatocellular Carcinoma Xenografts. Cancers. 2021;13:3977. https:\/\/doi.org\/10.3390\/cancers13163977.","journal-title":"Cancers"},{"key":"1454_CR21","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13550-024-01134-1","volume":"14","author":"LK Dickerson","year":"2024","unstructured":"Dickerson LK, Lehnert AL, Hamlin DK, Labadie KP, Goodsell KE, Liu Y, et al. Pilot study of humanized glypican-3-targeted zirconium-89 immuno-positron emission tomography for hepatocellular carcinoma. EJNMMI Res. 2024;14:74. https:\/\/doi.org\/10.1186\/s13550-024-01134-1.","journal-title":"EJNMMI Res"},{"key":"1454_CR22","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13550-018-0374-8","volume":"8","author":"JA Carrasquillo","year":"2018","unstructured":"Carrasquillo JA, O\u2019Donoghue JA, Beylergil V, Ruan S, Pandit-Taskar N, Larson SM, et al. I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma. EJNMMI Res. 2018;8:20. https:\/\/doi.org\/10.1186\/s13550-018-0374-8.","journal-title":"EJNMMI Res"},{"key":"1454_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/4564707","volume":"2019","author":"AD Ludwig","year":"2019","unstructured":"Ludwig AD, Labadie KP, Seo YD, Hamlin DK, Nguyen HM, Mahadev VM, et al. Yttrium-90-Labeled Anti-Glypican 3 Radioimmunotherapy Halts Tumor Growth in an Orthotopic Xenograft Model of Hepatocellular Carcinoma. J Oncol. 2019;2019:1\u20137. https:\/\/doi.org\/10.1155\/2019\/4564707.","journal-title":"J Oncol"},{"key":"1454_CR24","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/molecules26010004","volume":"26","author":"MM Bell","year":"2020","unstructured":"Bell MM, Gutsche NT, King AP, Baidoo KE, Kelada OJ, Choyke PL, et al. Glypican-3-Targeted Alpha Particle Therapy for Hepatocellular Carcinoma. Molecules. 2020;26:4. https:\/\/doi.org\/10.3390\/molecules26010004.","journal-title":"Molecules"},{"key":"1454_CR25","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.2967\/jnumed.121.262562","volume":"63","author":"KP Labadie","year":"2022","unstructured":"Labadie KP, Hamlin DK, Kenoyer A, Daniel SK, Utria AF, Ludwig AD, et al. Glypican-3-Targeted 227Th \u03b1-Therapy Reduces Tumor Burden in an Orthotopic Xenograft Murine Model of Hepatocellular Carcinoma. J Nucl Med. 2022;63:1033\u20138. https:\/\/doi.org\/10.2967\/jnumed.121.262562","journal-title":"J Nucl Med"},{"key":"1454_CR26","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.1038\/s41598-021-82172-w","volume":"11","author":"KP Labadie","year":"2021","unstructured":"Labadie KP, Ludwig AD, Lehnert AL, Hamlin DK, Kenoyer AL, Sullivan KM, et al. Glypican-3 targeted delivery of 89Zr and 90Y as a theranostic radionuclide platform for hepatocellular carcinoma. Sci Rep. 2021;11:3731. https:\/\/doi.org\/10.1038\/s41598-021-82172-w.","journal-title":"Sci Rep"},{"key":"1454_CR27","doi-asserted-by":"publisher","first-page":"ND09","DOI":"10.1158\/1538-7445.AM2025-ND09","volume":"85","author":"J Karlsson","year":"2025","unstructured":"Karlsson J, Siegel F, Moen I, Scholz A, Mobergslien A, Suurs F, et al. Abstract ND09: BAY 3547926: Novel targeted radionuclide therapy for hepatocellular carcinoma. Cancer Res. 2025;85:ND09\u201309. https:\/\/doi.org\/10.1158\/1538-7445.AM2025-ND09.","journal-title":"Cancer Res"},{"key":"1454_CR28","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3109\/08923973.2014.945126","volume":"36","author":"S Farajnia","year":"2014","unstructured":"Farajnia S, Ahmadzadeh V, Tanomand A, Veisi K, Khosroshahi SA, Rahbarnia L. Development trends for generation of single-chain antibody fragments. Immunopharmacol Immunotoxicol. 2014;36:297\u2013308. https:\/\/doi.org\/10.3109\/08923973.2014.945126.","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"1454_CR29","doi-asserted-by":"publisher","first-page":"ltae006","DOI":"10.1093\/immadv\/ltae006","volume":"4","author":"K Zeven","year":"2024","unstructured":"Zeven K, Lauwers Y, De Mey L, Debacker JM, De Pauw T, De Groof TWM, et al. Advancements in nuclear imaging using radiolabeled nanobody tracers to support cancer immunotherapy. Immunother Adv. 2024;4:ltae006. https:\/\/doi.org\/10.1093\/immadv\/ltae006.","journal-title":"Immunother Adv"},{"key":"1454_CR30","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.2967\/jnumed.114.145102","volume":"55","author":"JG Sham","year":"2014","unstructured":"Sham JG, Kievit FM, Grierson JR, Chiarelli PA, Miyaoka RS, Zhang M, et al. Glypican-3\u2013Targeting F(ab\u2032)2 for 89Zr PET of Hepatocellular Carcinoma. J Nucl Med. 2014;55:2032\u20137. https:\/\/doi.org\/10.2967\/jnumed.114.145102.","journal-title":"J Nucl Med"},{"key":"1454_CR31","first-page":"7422","volume":"11","author":"L Guan","year":"2019","unstructured":"Guan L, Wu W, Pang H, Duan D, Li S. Anti-GPC3 single-chain scFv antibody acts as an agent for radio-immunoimaging in diagnosing hepatocellular carcinoma. Am J Transl Res. 2019;11:7422\u201331.","journal-title":"Am J Transl Res"},{"key":"1454_CR32","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1021\/acs.molpharmaceut.5b00132","volume":"12","author":"H Hanaoka","year":"2015","unstructured":"Hanaoka H, Nagaya T, Sato K, Nakamura Y, Watanabe R, Harada T, et al. Glypican-3 Targeted Human Heavy Chain Antibody as a Drug Carrier for Hepatocellular Carcinoma Therapy. Mol Pharm. 2015;12:2151\u20137. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.5b00132.","journal-title":"Mol Pharm"},{"key":"1454_CR33","first-page":"P545","volume":"64","author":"Z Lin","year":"2023","unstructured":"Lin Z, Zhang X, Yuan F, Lv X, Song X, Long Y, et al. GPC3-targeted immunoPET imaging based on a fully human Fab fragment for precise diagnosis of hepatocellular carcinomas. J Nucl Med. 2023;64:P545.","journal-title":"J Nucl Med"},{"key":"1454_CR34","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-1856","author":"Z Lin","year":"2025","unstructured":"Lin Z, Li M, Pan Z, Hu W, Feng Y, Zhang X, et al. Glypican-3-Targeted PET Imaging for Precise Diagnosis of Hepatocellular Carcinoma: From Bench to Bedside. Clin Cancer Res Off J Am Assoc Cancer Res. 2025. https:\/\/doi.org\/10.1158\/1078-0432.CCR-25-1856.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"1454_CR35","first-page":"252051","volume":"66","author":"Z Lin","year":"2025","unstructured":"Lin Z, Feng Y, Zhang X, Song W, Gai Y, Jiang D, et al. Novel Anti-Glypican-3 Antibody Probes for Targeted Radioimmunotherapy in Hepatocellular Carcinoma. J Nucl Med. 2025;66:252051.","journal-title":"J Nucl Med"},{"key":"1454_CR36","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1007\/s00259-022-05723-x","volume":"49","author":"S An","year":"2022","unstructured":"An S, Zhang D, Zhang Y, Wang C, Shi L, Wei W, et al. GPC3-targeted immunoPET imaging of hepatocellular carcinomas. Eur J Nucl Med Mol Imaging. 2022;49:2682\u201392. https:\/\/doi.org\/10.1007\/s00259-022-05723-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1454_CR37","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.2967\/jnumed.122.265171","volume":"64","author":"S Fayn","year":"2023","unstructured":"Fayn S, King AP, Gutsche NT, Duan Z, Buffington J, Olkowski CP, et al. Site-Specifically Conjugated Single-Domain Antibody Successfully Identifies Glypican-3\u2013Expressing Liver Cancer by Immuno-PET. J Nucl Med. 2023;64:1017\u201323. https:\/\/doi.org\/10.2967\/jnumed.122.265171.","journal-title":"J Nucl Med"},{"key":"1454_CR38","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/psc.1400","volume":"17","author":"YL Lee","year":"2011","unstructured":"Lee YL, Ahn B, Lee Y, Lee S, Cho J, Lee J. Targeting of hepatocellular carcinoma with glypican-3\u2010targeting peptide ligand. J Pept Sci. 2011;17:763\u20139. https:\/\/doi.org\/10.1002\/psc.1400.","journal-title":"J Pept Sci"},{"key":"1454_CR39","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1021\/acs.bioconjchem.6b00030","volume":"27","author":"D Zhu","year":"2016","unstructured":"Zhu D, Qin Y, Wang J, Zhang L, Zou S, Zhu X, et al. Novel Glypican-3-Binding Peptide for in Vivo Hepatocellular Carcinoma Fluorescent Imaging. Bioconjug Chem. 2016;27:831\u20139. https:\/\/doi.org\/10.1021\/acs.bioconjchem.6b00030.","journal-title":"Bioconjug Chem"},{"key":"1454_CR40","doi-asserted-by":"publisher","first-page":"5656","DOI":"10.1039\/D0BM00943A","volume":"8","author":"Y Qin","year":"2020","unstructured":"Qin Y, Cheng S, Li Y, Zou S, Chen M, Zhu D, et al. The development of a Glypican-3-specific binding peptide using in vivo and in vitro two-step phage display screening for the PET imaging of hepatocellular carcinoma. Biomater Sci. 2020;8:5656\u201365. https:\/\/doi.org\/10.1039\/D0BM00943A.","journal-title":"Biomater Sci"},{"key":"1454_CR41","doi-asserted-by":"publisher","first-page":"1600335","DOI":"10.1002\/mabi.201600335","volume":"17","author":"Z Qin","year":"2017","unstructured":"Qin Z, Wang J, Wang Y, Wang G, Wang X, Zhou Z, et al. Identification of a Glypican-3\u2010Binding Peptide for In Vivo Non\u2010Invasive Human Hepatocellular Carcinoma Detection. Macromol Biosci. 2017;17:1600335. https:\/\/doi.org\/10.1002\/mabi.201600335.","journal-title":"Macromol Biosci"},{"key":"1454_CR42","doi-asserted-by":"publisher","first-page":"110498","DOI":"10.1016\/j.colsurfb.2019.110498","volume":"184","author":"S Feng","year":"2019","unstructured":"Feng S, Zhou J, Li Z, Appelman HD, Zhao L, Zhu J, et al. Sorafenib encapsulated in nanocarrier functionalized with glypican-3 specific peptide for targeted therapy of hepatocellular carcinoma. Colloids Surf B Biointerfaces. 2019;184:110498. https:\/\/doi.org\/10.1016\/j.colsurfb.2019.110498.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"1454_CR43","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1039\/C8BM01016A","volume":"7","author":"Q Zhang","year":"2019","unstructured":"Zhang Q, Han Z, Tao J, Zhao M, Zhang W, Li P, et al. An innovative peptide with high affinity to GPC3 for hepatocellular carcinoma diagnosis. Biomater Sci. 2019;7:159\u201367. https:\/\/doi.org\/10.1039\/C8BM01016A.","journal-title":"Biomater Sci"},{"key":"1454_CR44","doi-asserted-by":"publisher","unstructured":"Zhang Q, Han Z, Zhang W, Qian Z, Gu Y. In vivo imaging of hepatocellular carcinoma using a glypican-3-binding peptide based probe. In: Achilefu S, Raghavachari R, editors. San Francisco, California, United States; 2017 [cited 2025 Sept 17]. p. 100790T. https:\/\/doi.org\/10.1117\/12.2251310","DOI":"10.1117\/12.2251310"},{"key":"1454_CR45","doi-asserted-by":"publisher","first-page":"679336","DOI":"10.3389\/fonc.2021.679336","volume":"11","author":"J Yan","year":"2021","unstructured":"Yan J, Yu X, Chen X, Liu F, Chen F, Ding N, et al. Identification of a Glypican-3 Binding Peptide From a Phage-Displayed Peptide Library for PET Imaging of Hepatocellular Carcinoma. Front Oncol. 2021;11:679336. https:\/\/doi.org\/10.3389\/fonc.2021.679336.","journal-title":"Front Oncol"},{"key":"1454_CR46","doi-asserted-by":"publisher","first-page":"19714","DOI":"10.1021\/acs.jmedchem.5c02081","volume":"68","author":"G Chen","year":"2025","unstructured":"Chen G, Zhou G, Sun X, Cui Z, Yang H, Wang C, et al. 10P3Me: A GPC3-Targeted Peptide PET Probe for Subcutaneous and Orthotopic HCC Imaging. J Med Chem. 2025;68:19714\u201325. https:\/\/doi.org\/10.1021\/acs.jmedchem.5c02081.","journal-title":"J Med Chem"},{"key":"1454_CR47","doi-asserted-by":"publisher","first-page":"586","DOI":"10.2967\/jnumed.123.266766","volume":"65","author":"F Lin","year":"2024","unstructured":"Lin F, Clift R, Ehara T, Yanagida H, Horton S, Noncovich A, et al. Peptide Binder to Glypican-3 as a Theranostic Agent for Hepatocellular Carcinoma. J Nucl Med. 2024;65:586\u201392. https:\/\/doi.org\/10.2967\/jnumed.123.266766.","journal-title":"J Nucl Med"},{"key":"1454_CR48","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s00726-017-2517-z","volume":"50","author":"Z Wang","year":"2018","unstructured":"Wang Z, Han Y-J, Huang S, Wang M, Zhou W-L, Li H-S, et al. Imaging the expression of glypican-3 in hepatocellular carcinoma by PET. Amino Acids. 2018;50:309\u201320. https:\/\/doi.org\/10.1007\/s00726-017-2517-z.","journal-title":"Amino Acids"},{"key":"1454_CR49","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1007\/s11307-019-01356-z","volume":"22","author":"Y Li","year":"2020","unstructured":"Li Y, Zhang J, Gu J, Hu K, Huang S, Conti PS, et al. Radiofluorinated GPC3-Binding Peptides for PET Imaging of Hepatocellular Carcinoma. Mol Imaging Biol. 2020;22:134\u201343. https:\/\/doi.org\/10.1007\/s11307-019-01356-z.","journal-title":"Mol Imaging Biol"},{"key":"1454_CR50","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1021\/acs.molpharmaceut.1c00060","volume":"18","author":"H Xu","year":"2021","unstructured":"Xu H, Tang Y, Zhao Y, Wang F, Gao X, Deng D, et al. SPECT Imaging of Hepatocellular Carcinoma Detection by the GPC3 Receptor. Mol Pharm. 2021;18:2082\u201390. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.1c00060.","journal-title":"Mol Pharm"},{"key":"1454_CR51","doi-asserted-by":"publisher","first-page":"107352","DOI":"10.1016\/j.bioorg.2024.107352","volume":"147","author":"C Mo","year":"2024","unstructured":"Mo C, Sun P, Liang H, Chen Z, Wang M, Fu L, et al. Synthesis and preclinical evaluation of a novel probe [18F]AlF-NOTA-IPB-GPC3P for PET imaging of GPC3 positive tumor. Bioorg Chem. 2024;147:107352. https:\/\/doi.org\/10.1016\/j.bioorg.2024.107352.","journal-title":"Bioorg Chem"},{"key":"1454_CR52","doi-asserted-by":"publisher","first-page":"4021","DOI":"10.1021\/acsptsci.4c00504","volume":"7","author":"Z Li","year":"2024","unstructured":"Li Z, Mo C, Li C, Wang Q, Huang S, Huang Y, et al. Gallium-68 Labeled Positron Emission Computed Tomography Tracer Targeting Glypican-3 with High Contrast for Hepatocellular Carcinoma Imaging. ACS Pharmacol Transl Sci. 2024;7:4021\u201331. https:\/\/doi.org\/10.1021\/acsptsci.4c00504.","journal-title":"ACS Pharmacol Transl Sci"},{"key":"1454_CR53","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1021\/acs.molpharmaceut.4c00838","volume":"22","author":"L Chen","year":"2025","unstructured":"Chen L, Cheng S, Zhu D, Bao G, Wang Z, Deng X, et al. Synthesis and Preclinical Evaluation of Dual-Specific Probe Targeting Glypican-3 and Prostate-Specific Membrane Antigen for Hepatocellular Carcinoma PET Imaging. Mol Pharm. 2025;22:209\u201320. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.4c00838.","journal-title":"Mol Pharm"},{"key":"1454_CR54","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1089\/cbr.2019.2888","volume":"34","author":"RM Berman","year":"2019","unstructured":"Berman RM, Kelada OJ, Gutsche NT, Natarajan R, Swenson RE, Fu Y, et al. Vitro Performance of Published Glypican 3-Targeting Peptides TJ12P1 and L5 Indicates Lack of Specificity and Potency. Cancer Biother Radiopharm. 2019;34:498\u2013503. https:\/\/doi.org\/10.1089\/cbr.2019.2888.","journal-title":"Cancer Biother Radiopharm"},{"key":"1454_CR55","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.3390\/ph18111656","volume":"18","author":"E-M Burger","year":"2025","unstructured":"Burger E-M, Hill C, Wodtke R, Zarschler K, Laube M, Donat CK, et al. In Vitro Characterization of the Published Glypican-3-Targeting Peptide TJ12P2 Reveals a Lack of Specificity and Potency. Pharmaceuticals. 2025;18:1656. https:\/\/doi.org\/10.3390\/ph18111656.","journal-title":"Pharmaceuticals"},{"key":"1454_CR56","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.2967\/jnumed.124.268147","volume":"65","author":"AJ Poot","year":"2024","unstructured":"Poot AJ, Lapa C, Weber WA, Lam MGEH, Eiber M, Dierks A, et al. [68Ga]Ga-RAYZ-8009: A Glypican-3\u2013Targeted Diagnostic Radiopharmaceutical for Hepatocellular Carcinoma Molecular Imaging\u2014A First-in-Human Case Series. J Nucl Med. 2024;65:1597\u2013603. https:\/\/doi.org\/10.2967\/jnumed.124.268147.","journal-title":"J Nucl Med"},{"key":"1454_CR57","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.2967\/jnumed.125.270267","volume":"66","author":"O Viering","year":"2025","unstructured":"Viering O, Brosch-Lenz J, Bundschuh RA, Scholtissek H, Enke JS, Amerein A, et al. Biodistribution and Radiation Dosimetry of [68Ga]Ga-RAYZ-8009, a Glypican 3\u2013Targeting Compound for Imaging of Hepatocellular Carcinoma. J Nucl Med Soc Nuclear Med. 2025;66:1737\u201342. https:\/\/doi.org\/10.2967\/jnumed.125.270267.","journal-title":"J Nucl Med Soc Nuclear Med"},{"key":"1454_CR58","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1039\/D2CB00094F","volume":"3","author":"R Luo","year":"2022","unstructured":"Luo R, Liu H, Cheng Z. Protein scaffolds: antibody alternatives for cancer diagnosis and therapy. RSC Chem Biol. 2022;3:830\u201347. https:\/\/doi.org\/10.1039\/D2CB00094F.","journal-title":"RSC Chem Biol"},{"key":"1454_CR59","doi-asserted-by":"publisher","first-page":"8680","DOI":"10.3390\/ijms24108680","volume":"24","author":"F Gabriele","year":"2023","unstructured":"Gabriele F, Palerma M, Ippoliti R, Angelucci F, Pitari G, Ardini M. Recent Advances on Affibody- and DARPin-Conjugated Nanomaterials in Cancer Therapy. Int J Mol Sci. 2023;24:8680. https:\/\/doi.org\/10.3390\/ijms24108680.","journal-title":"Int J Mol Sci"},{"key":"1454_CR60","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1093\/protein\/gzy013","volume":"31","author":"D Lipov\u0161ek","year":"2018","unstructured":"Lipov\u0161ek D, Carvajal I, Allentoff AJ, Barros A, Brailsford J, Cong Q, et al. Adnectin\u2013drug conjugates for Glypican-3-specific delivery of a cytotoxic payload to tumors. Protein Eng Des Sel. 2018;31:159\u201371. https:\/\/doi.org\/10.1093\/protein\/gzy013.","journal-title":"Protein Eng Des Sel"},{"key":"1454_CR61","doi-asserted-by":"publisher","first-page":"151","DOI":"10.21037\/qims.2018.01.09","volume":"8","author":"M Zhao","year":"2018","unstructured":"Zhao M, Dong L, Liu Z, Yang S, Wu W, Lin J. In vivo fluorescence imaging of hepatocellular carcinoma using a novel GPC3-specific aptamer probe. Quant Imaging Med Surg. 2018;8:151\u201360. https:\/\/doi.org\/10.21037\/qims.2018.01.09.","journal-title":"Quant Imaging Med Surg"},{"key":"1454_CR62","doi-asserted-by":"publisher","unstructured":"Zhao M, Liu Z, Dong L, Zhou H, Yang S, Wu W et al. A GPC3-specific aptamer-mediated magnetic resonance probe for hepatocellular carcinoma. Int J Nanomed 2018;Volume 13:4433\u201343. https:\/\/doi.org\/10.2147\/IJN.S168268","DOI":"10.2147\/IJN.S168268"},{"key":"1454_CR63","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.biochi.2020.02.007","volume":"171\u2013172","author":"G-X Zhang","year":"2020","unstructured":"Zhang G-X, Liu Y-L, Yang M, Huang W-S, Xu J-H. An aptamer-based, fluorescent and radionuclide dual-modality probe. Biochimie. 2020;171\u2013172:55\u201362. https:\/\/doi.org\/10.1016\/j.biochi.2020.02.007.","journal-title":"Biochimie"},{"key":"1454_CR64","doi-asserted-by":"publisher","first-page":"4010","DOI":"10.7150\/thno.72949","volume":"12","author":"L Bohrmann","year":"2022","unstructured":"Bohrmann L, Burghardt T, Haynes C, Saatchi K, H\u00e4feli UO. Aptamers used for molecular imaging and theranostics - recent developments. Theranostics. 2022;12:4010\u201350. https:\/\/doi.org\/10.7150\/thno.72949.","journal-title":"Theranostics"},{"key":"1454_CR65","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1021\/acs.molpharmaceut.2c00760","volume":"20","author":"S Ghosh","year":"2023","unstructured":"Ghosh S, Fletcher NL, Huda P, Houston ZH, Howard CB, Lund ME, et al. Pharmacokinetics and Biodistribution of 89Zr-Miltuximab and Its Antibody Fragments as Glypican-1 Targeting Immuno-PET Agents in Glioblastoma. Mol Pharm. 2023;20:1549\u201363. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.2c00760.","journal-title":"Mol Pharm"},{"key":"1454_CR66","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/abt\/tbaa024","volume":"3","author":"MP Deonarain","year":"2020","unstructured":"Deonarain MP, Xue Q. Tackling solid tumour therapy with small-format drug conjugates. Antib Ther. 2020;3:237\u201345. https:\/\/doi.org\/10.1093\/abt\/tbaa024.","journal-title":"Antib Ther"},{"key":"1454_CR67","doi-asserted-by":"publisher","first-page":"2085535","DOI":"10.1080\/19420862.2022.2085535","volume":"14","author":"H Rafidi","year":"2022","unstructured":"Rafidi H, Rajan S, Urban K, Shatz-Binder W, Hui K, Ferl GZ, et al. Effect of molecular size on interstitial pharmacokinetics and tissue catabolism of antibodies. mAbs. 2022;14:2085535. https:\/\/doi.org\/10.1080\/19420862.2022.2085535.","journal-title":"mAbs"}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-026-01454-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-026-01454-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-026-01454-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T22:58:05Z","timestamp":1785106685000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13550-026-01454-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1454"],"URL":"https:\/\/doi.org\/10.1186\/s13550-026-01454-4","relation":{},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"assertion":[{"value":"12 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. Regarding the reuse of figures, Fig.\u00a01 is reproduced from an open-access article (CC BY-NC 4.0). Figures\u00a02 and 3 are reproduced from the Journal of Nuclear Medicine (JNM). According to JNM\u2019s official permission policy, formal written permission is not required for non-commercial reuse of figures in peer-reviewed journals. Appropriate credit lines have been provided in the respective figure legends.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"112"}}